Also known as LY-3437943.
chemXplore tracks 2 projects producing retatrutide, of which 2 are active.
1 new construction and 1 expansion.
Owners and developers: Eli Lilly and Company (1), Lilly (1)
Investors: Eli Lilly and Company (1)
Contractors are recorded on 1 of these 2 projects For subscribers
Combination achieved up to 23.3% weight loss (54.1 lbs) and 2.9% A1C reduction versus 14.8% (34.4 lbs) and 2.4% with tirzepatide; Phase 3 to start Q4 2026.
Triple agonist produced up to 20.8% weight loss and up to 1.6% A1C reduction at 80 weeks in adults with type 2 diabetes and obesity.
Phase 3 retatrutide and Foundayo results show large weight and A1C reductions and signals of cardiovascular benefit; Phase 2 eloraTZP and additional Mounjaro/Zepbound analyses also presented.
Revenue rose 48% to $23.0bn driven by Mounjaro and Zepbound; updated 2026 revenue guidance to $85–87bn; retatrutide Phase 3 package complete supporting a Q1 2027 BLA.
First‑in‑class triple agonist delivered large 80‑week weight losses and meaningful A1C and cardiometabolic improvements in difficult‑to‑treat obesity populations.
Phase II starts for a potential first‑in‑class triple GLP‑1/GIP/NPY2 receptor agonist targeting weight, satiety and central hunger signalling; study includes dose finding and safety/efficacy evaluation.
Phase 3 TRIUMPH-1: three doses met endpoints at 80 weeks with dose-related, substantial weight loss. 104-week extension in BMI≥35 showed further loss; cardiometabolic markers improved; GI AEs common.
Buildout now totals $21B in Indiana since 2020; upgrades at Lebanon API to produce Foundayo, Zepbound/Mounjaro and retatrutide; project to scale API capacity and boost regional jobs and GDP.
The new facility will create 2,800 jobs, produce weight-loss medicines, and boost the local economy with advanced technologies and partnerships in education and workforce development.
